Dual RAS therapy not on target, but fully alive

Nephron - Clinical Practice

Volumn 116, Issue 2, 2010, Pages

  Lambers Heerspink, H J ^a   De Zeeuw, D ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chronic kidney disease; Hyperkalemia; Renin angiotensin system

Indexed keywords

ALBUMIN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; POTASSIUM; RAMIPRIL; SARTAN DERIVATIVE; TELMISARTAN;

ALBUMINURIA; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; STUDY DESIGN;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY DISEASES; RENIN-ANGIOTENSIN SYSTEM;

EID: 77952840635     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315882     Document Type: Short Survey

References (35)

1. Cohen DL, Townsend RR: I s there added val-ue to adding ARB to ACE inhibitors in the management of CKD? J Am Soc Nephrol 2009; 20: 1666-1668.
2. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Pfeffer MA: Dual renin-an-giotensin system blockade and kidney dis-ease. J Am Coll Cardiol 2009; 54: 278-280.
3. Ruggenenti P, Remuzzi G. Proteinuria: Is the ONTARGET renal substudy actually off tar-get? Nat Rev Nephrol 2009; 5:436-437.
4. Epstein M: Re-examining RAS-blocking treatment regimens for abrogating progres-sion of chronic kidney disease. Nat Clin Pract Nephrol 2009; 5:12-13.
5. Messerli FH: The sudden demise of dual re-nin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 2009; 53: 468-470.
6. Berns JS: Is angiotensin-converting enzyme inhibitor and angiotensin receptor blocker combination therapy better than monother-apy and safe in patients with CKD? Am J Kidney Dis 2009; 53: 192-196.
7. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruper-ez M, Egido J: Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001; 10:321-329.
8. Suzuki Y, Ruiz-Ortega M, Gomez-Guerrero C, Tomino Y, Egido J: Angiotensin II, the im-mune system and renal diseases: another road for RAS? Nephrol Dial Transplant 2003; 18: 1423-1426.
9. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339:1448-1456.
10. Yoshioka T, Rennke HG, Salant DJ, Deen WM, Ichikawa I: Role of abnormally high transmural pressure in the permselectivity defect of glomerular capillary wall: a study in early passive Heymann nephritis. Circ Res 1987; 61: 531-538.
11. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G: Renoprotective properties of ACE-inhibition in non-diabetic nephropa-thies with non-nephrotic proteinuria. Lan-cet 1999; 354: 359-364.
12. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW: Efficacy and safety of benazepril for advanced chronic renal insuf-ficiency. N Engl J Med 2006; 354: 131-140.
13. Brenner BM, Cooper ME, de Zeeuw D Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascu-lar outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
14. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angio-tensin-receptor antagonist irbesartan in pa-tients with nephropathy due to type 2 diabe-tes. N Engl J Med 2001; 345: 851-860.
15. Kunz R, Friedrich C, Wolbers M, Mann JF: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48.
16. Rossing P, Hommel E, Smidt UM, Parving HH: Reduction in albuminuria predicts a beneficial effect on diminishing the progres-sion of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994; 37: 511-516.
17. Apperloo AJ, de Zeeuw D, de Jong PE: Short-term antiproteinuric response to antihyper-tensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int Suppl 1994; 45:S174-S178.
18. De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Coo-per ME, Mitch WE, Brenner BM: Protein-uria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320. (Pubitemid 38670018)
19. Eijkelkamp WB, Zhang Z, Remuzzi G, Parv-ing HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post-hoc analysis from the Reduction of End-points in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540-1546.
20. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, DeFerrari G, Drury P, Locatelli F, Wiegmann TB, Lewis EJ: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45:281-287.
21. Parving HH, Lehnert H, Brochner-Mor-tensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
22. Rossing K, Christensen PK, Andersen S, Ho-vind P, Hansen HP, Parving HH: Compara-tive effects of irbesartan on ambulatory and office blood pressure: a substudy of ambula-tory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microal-buminuria study. Diabetes Care 2003; 26: 569-574.
23. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R Watts RW, Cooper ME: Ran-domised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin-dependent diabetes: the Candesar-tan and Lisinopril Microalbuminuria (CALM) study. BMJ 2000; 321(7274):1440-1444.
24. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treat-ment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361:117-124. (Pubitemid 36092015)
25. Kunz R, Wolbers M, Glass T, Mann JF: The COOPERATE trial: a letter of concern. Lan-cet 2008; 371:1575-1576.
26. Bidani A: Controversy about COOPERATE ABPM trial data. Am J Nephrol 2006; 26: 629-632.
27. Retraction-Combination treatment of an-giotensin-II receptor blocker and angioten-sin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2009; 374: 1226.
28. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, An-derson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
29. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Mag-gioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkho-menko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.
30. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Re-muzzi G, Levey AS: Proteinuria as a modifi-able risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60: 1131-1140.
31. Vogt L, Navis G, de Zeeuw D: Individual ti-tration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy? J Am Soc Nephrol 2005; 16(suppl 1):S53-S57.
32. Frimodt-Moller M, Hoj Nielsen A, Strand-gaard S, Kamper AL: Feasibility of com-bined treatment with enalapril and cande-sartan in advanced chronic kidney disease. Nephrol Dial Transplant 2010;25:842-847.
33. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Sha-hinfar S, Toto R, Levey AS: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angioten-sin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252.
34. De Zeeuw D, Heerspink HL, Gansevoort RT, Bakker SJL: How to improve renal outcome in diabetes and hypertension-the impor-tance of early screening for and treatment of microalbuminuria. Eur Nephrol 2009; 3: 13-15.
35. Maione A, Nicolucci A, Craig JC, Tognoni G, Moschetta A, Palasciano G, Pugliese G, Procaccini DA, Gesualdo L, Pellegrini F, Strippoli GF: Protocol of the Long-term Im-pact of RAS Inhibition on Cardiorenal Out-comes (LIRICO) randomized trial. J Nephrol 2007; 20:646-655.